trevena shares tripled to 190 monday after the company said formal regulatory approval was granted in china for olinvyk to be sold as a painkiller by jiangsu nhwa its partner in china with an exclusive license agreement for the drugs development and commercialization in the country the stock hit its 52week low of 58 cents